

1 ARNOLD & PORTER LLP
 MAURICE A. LEITER (State Bar No. 123732)
 2 maury.leiter@aporter.com
 777 South Figueroa Street, 44th Floor
 3 Los Angeles, California 90017-5844
 Telephone: +1 213.243.4000
 4 Facsimile: +1 213.243.4199

5 ARNOLD & PORTER LLP
 6 MICHAEL J. BAKER (State Bar No. 56492)
 michael.baker@aporter.com
 7 SHARON D. MAYO (State Bar No. 150469)
 sharon.mayo@aporter.com
 8 Three Embarcadero Center, 10th Floor
 9 San Francisco, California 94111-4024
 Telephone: +1 415.471.3100
 10 Facsimile: +1 415.471.3400

11 *Attorneys for Defendant Bristol-Myers Squibb Company*

12 [Additional Counsel Listed At Signature Page]

14 UNITED STATES DISTRICT COURT
 15 NORTHERN DISTRICT OF CALIFORNIA
 16 SAN FRANCISCO DIVISION

16 JAMES BLAIR *et al.*,
 17
 Plaintiff,
 18
 v.
 19
 20 BRISTOL-MYERS SQUIBB COMPANY,
 MCKESSON CORPORATION, and
 21 DOES 1 to 100,
 22 Defendants.
 23

No. 14-2515 EMC

**JOINT STIPULATION AND
 [PROPOSED] ORDER TO STAY
 LITIGATION PENDING TRANSFER TO
 THE PLAVIX® MDL**

Judge: Hon. Edward M. Chen

1 This Joint Stipulation is made by and between Plaintiffs in *Blair et al. v. Bristol-Myers*
2 *Squibb Co. et al.*, No. CV-14-2515 EMC (N.D. Cal.), and Defendant Bristol-Myers Squibb
3 Company (“BMS”) (collectively “the Parties”), by and through the undersigned counsel of record,
4 with reference to the following facts:

5 1. WHEREAS, on February 12, 2013, the Judicial Panel on Multidistrict Litigation
6 (“JPML”) established a multidistrict Plavix® litigation in the District of New Jersey, assigned to
7 Judge Freda Wolfson;

8 2. WHEREAS, on May 30, 2014, Plaintiffs filed the *Blair* action in the Superior Court
9 of California, San Francisco County;

10 3. WHEREAS, on June 2, 2014, the *Blair* action was removed to this Court by
11 Defendant BMS;

12 4. WHEREAS, on June 11, 2014, Defendant BMS tagged this case for transfer to the
13 Plavix® MDL and anticipates that the JPML will issue a conditional transfer order for this case
14 soon; and

15 5. WHEREAS, the parties agree that the *Blair* action should be stayed pending its
16 anticipated transfer to the Plavix® MDL in the District of New Jersey.

17
18 THEREFORE, IT IS HEREBY STIPULATED AND AGREED, subject to the Court’s
19 approval, that the *Blair* action should be stayed pending its anticipated transfer to the Plavix® MDL
20 in the District of New Jersey.

21
22 **IT IS SO STIPULATED.**
23
24
25
26
27
28

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Dated: June 11, 2014

Joshua C. Ezrin
AUDET & PARTNERS, LLP
221 Main Street, Suite 1460
San Francisco, CA 94105

Daniel C. Burke
PARKER WAICHMAN LLP
6 Harbor Park Drive
Port Washington, New York 11050

By: /s/ Joshua C. Ezrin
Joshua C. Ezrin

Attorney for Plaintiffs

Dated: June 11, 2014

ARNOLD & PORTER LLP
Three Embarcadero Center, 10th Floor
San Francisco, CA 94111

By: /s/ Sharon D. Mayo
Sharon D. Mayo

*Attorney for Defendant
Bristol-Myers Squibb Company*

PURSUANT TO STIPULATION, IT IS SO ORDERED.

Date: 6/13/14

Judge Edward M. Chen
U.S. District J



1 I, Sharon D. Mayo, am the ECF User whose ID and password are being used to file this
2 Stipulation and [Proposed] Order to Stay Litigation Pending Transfer to the Plavix® MDL. In
3 compliance with General Order 45, X.B, I hereby attest that Joshua C. Ezrin has concurred in this
4 filing.

5
6 Dated: June 11, 2014

ARNOLD & PORTER LLP

7
8 By: /s/ Sharon D. Mayo

9 Sharon D. Mayo

10 *Attorney for Defendant*
11 *Bristol-Myers Squibb Company*
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28